Johnson & Johnson
Healthcare Product Manufacturers, Health Service Providers
'%20fill='%23FFFFFF'%3E%3Crect%20x='249'%20y='126'%20width='1'%20height='1'%3E%3C/rect%3E%3C/g%3E%3C/g%3E%3C/svg%3E)
2025Year7Month16Day, Johnson & Johnson (NYSE:JNJ) Officially Announced2025Q2 Performance Report of the Year. The report shows that the company delivered a strong performance in this quarter. “Transcript”, and at the same time, based on this positive trend, adjusted upward2025Full-year performance forecast for China.
From the financial data,2025In the second quarter of the year, Johnson & Johnson reported sales reaching237.43Billion USD, compared to2024Same period last year224.47Billion USD Growth5.8%; Net income is55.37Billion US dollars,2024The same period last year was46.86Billion USD, Increase18.2%; Diluted Earnings Per Share (EPS) for2.29Dollar,2024The same period last year was1.93Dollars, Growth18.7%. Under non-GAAP (Non-GAAP) In terms of operational sales growth4.6%, Adjusted operating sales growth3.0%; Adjusted net profit is66.99"Billion US dollars,"2024The same period last year was68.40Billion USD, Decrease2.1%; Adjusted diluted earnings per share is2.77Dollar,2024The same period last year was2.82Dollar, Decrease1.8%。
Regionally, salesOutstanding performance in the U.S. market,Sales in the second quarter were135.44 Billion US dollars,2024The same period last year was125.69Billion USD, reported sales growth7.8%, Sales Growth7.8%, Adjusted Operating Sales Growth5.0%。
International market sales are101.99Billion US dollars,2024In the same period last year98.78Billion dollars, reported sales growth3.2%, Sales Growth in Operations0.6%, Adjusted operational sales growth0.4%。
In terms of business segments,Innovative Drug (Innovative Medicine) Global sales were152.02Billion US dollars,2024The same period last year was144.90Billion dollars, reported sales growth4.9%, Increase in operating sales3.8%, Adjusted operating sales growth2.4%The growth was mainly driven by daratumumab in the oncology field (DARZALEX）、CARVYKTI, Apalutamide (ERLEADA`) and Amivantamab`/Lazertinib (RYBREVANT/LAZCLUZE), Guselkumab in the field of immunology (TREMFYA) and Golimumab (SIMPONI/SIMPONI ARIA`) and esketamine in the field of neuroscience (`SPRAVATO) Promote. However, in the field of immunology, ustekinumab (STELARA) Approximately1170A negative impact of base points and COVID-related businesses in the infectious disease field130A negative impact of base points partially offset the growth.
Medical Technology (MedTech) Global sales were85.41Billion US dollars,2024In the same period last year79.57Billion USD, reported sales growth7.3%, Sales Growth in Operations6.1%, Adjusted operational sales growth4.1%. Its growth is mainly driven by electrophysiology products in the cardiovascular field andAbiomedAnd wound closure products in the general surgery field.
In terms of product pipelines and key updates,Johnson & Johnson Achieves Multiple Advances.IMAAVYApproved for the treatment of generalized myasthenia gravis, the drug24The efficacy within the week is superior to existing similar drugs;TAR-200Granted Priority Review for Bladder Cancer Treatment with Disease-Free Survival Rate Exceeding80%；CARVYKTIBenefits shown in overall survival and progression-free survival in multiple myeloma; General surgical robotic systemsOTTAVAClinical trials are ongoing. In addition, several products have made significant progress in regulatory submissions, data releases, and product launches.
Johnson & Johnson Raises Guidance Based on Strong Operational Performance and Favorable Foreign Exchange Impact2025Full-year performance forecast for the year. The midpoint of the full-year sales forecast is expected to be raised.20Billion USD, to934Billion USD, year-on-year growth5.4%; Full-year earnings per share forecast raised0.25USD to10.85USD; Midpoint of Adjusted Operational Earnings Per Share Raised to10.68Dollar.
Overall, Johnson & Johnson2025The second quarter of the year showed a positive development trend in financial data, regional markets, and business segments. The active progress in the product pipeline and the upward revision of the full-year forecast have also led the market to anticipate strong subsequent performance.